Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. More Details
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Alphamab Oncology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 9966 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: 9966's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
7 Day Return
1 Year Return
Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned 34.6% over the past year.
Return vs Market: 9966 exceeded the Hong Kong Market which returned 20.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Alphamab Oncology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHave Insiders Been Selling Alphamab Oncology (HKG:9966) Shares?
1 month ago | Simply Wall StIs Alphamab Oncology (HKG:9966) Using Too Much Debt?
2 months ago | Simply Wall StWhat Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?
Is Alphamab Oncology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 9966 (HK$22.25) is trading below our estimate of fair value (HK$109.26)
Significantly Below Fair Value: 9966 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 9966 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 9966 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 9966's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 9966 is overvalued based on its PB Ratio (7.6x) compared to the HK Biotechs industry average (4.3x).
How is Alphamab Oncology forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9966 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9966 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9966 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9966's revenue (62% per year) is forecast to grow faster than the Hong Kong market (12.7% per year).
High Growth Revenue: 9966's revenue (62% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9966 is forecast to be unprofitable in 3 years.
How has Alphamab Oncology performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 9966 is currently unprofitable.
Growing Profit Margin: 9966 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 9966's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 9966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43.1%).
Return on Equity
High ROE: 9966 has a negative Return on Equity (-18.82%), as it is currently unprofitable.
How is Alphamab Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: 9966's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥329.5M).
Long Term Liabilities: 9966's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥36.9M).
Debt to Equity History and Analysis
Debt Level: 9966's debt to equity ratio (9.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 9966's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9966 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 9966 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 42.5% each year.
What is Alphamab Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 9966's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 9966's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9966's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9966's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 9966's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ting Xu (47 yo)
Dr. Ting Xu, Ph.D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008. Dr. Xu serves as Executive Director at Alphamab Oncology since ...
Experienced Management: 9966's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: 9966's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alphamab Oncology's company bio, employee growth, exchange listings and data sources
- Name: Alphamab Oncology
- Ticker: 9966
- Exchange: SEHK
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$20.822b
- Shares outstanding: 935.84m
- Website: https://www.alphamabonc.com
Number of Employees
- Alphamab Oncology
- Building C23
- Rooms 401 and 501
- Jiangsu Province
Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bisp...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/23 10:07|
|End of Day Share Price||2021/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.